8 research outputs found
NMR Metabolomic Analysis of Exhaled Breath Condensate of Asthmatic Patients at Two Different Temperatures
Exhaled
breath condensate (EBC) collection is a noninvasive method
to investigate lung diseases. EBC is usually collected with commercial/custom-made
condensers, but the optimal condensing temperature is often unknown.
As such, the physical and chemical properties of exhaled metabolites
should be considered when setting the temperature, therefore requiring
validation and standardization of the collecting procedure. EBC is
frequently used in nuclear magnetic resonance (NMR)-based metabolomics,
which unambiguously recognizes different pulmonary pathological states.
Here we applied NMR-based metabolomics to asthmatic and healthy EBC
samples collected with two commercial condensers operating at ā27.3
and ā4.8 Ā°C. Thirty-five mild asthmatic patients and 35
healthy subjects were included in the study, while blind validation
was obtained from 20 asthmatic and 20 healthy different subjects not
included in the primary analysis. We initially analyzed the samples
separately and assessed the within-day, between-day, and technical
repeatabilities. Next, samples were interchanged, and, finally, all
samples were analyzed together, disregarding the condensing temperature.
Partial least-squares discriminant analysis of NMR spectra correctly
classified samples, without any influence from the temperature. Input
variables were either integral bucket areas (spectral bucketing) or
metabolite concentrations (targeted profiling). We always obtained
strong regression models (95%), with high average-quality parameters
for spectral profiling (<i>R</i><sup>2</sup> = 0.84 and <i>Q</i><sup>2</sup> = 0.78) and targeted profiling (<i>R</i><sup>2</sup> = 0.91 and <i>Q</i><sup>2</sup> = 0.87). In
particular, although targeted profiling clustering is better than
spectral profiling, all models reproduced the relative metabolite
variations responsible for class differentiation. This warrants that
cross comparisons are reliable and that NMR-based metabolomics could
attenuate some specific problems linked to standardization of EBC
collection
Serum Levels of Acyl-Carnitines along the Continuum from Normal to Alzheimer's Dementia
<div><p>This study aimed to determine the serum levels of free L-carnitine, acetyl-L-carnitine and 34 acyl-L-carnitine in healthy subjects and in patients with or at risk of Alzheimerās disease. Twenty-nine patients with probable Alzheimerās disease, 18 with mild cognitive impairment of the amnestic type, 24 with subjective memory complaint and 46 healthy subjects were enrolled in the study, and the levels of carnitine and acyl-carnitines were measured by tandem mass spectrometry. The concentrations of acetyl-L-carnitine progressively decreased passing from healthy subjects group (meanĀ±SD, 5.6Ā±1.3 Ī¼mol/L) to subjective memory complaint (4.3Ā±0.9 Ī¼mol/L), mild cognitive impairment (4.0Ā±0.53 Ī¼mol/L), up to Alzheimerās disease (3.5Ā±0.6 Ī¼mol/L) group (p<0.001). The differences were significant for the comparisons: healthy subjects vs. subjective memory complaint, mild cognitive impairment or Alzheimerās disease group; and subjective memory complaint vs. Alzheimerās disease group. Other acyl-carnitines, such as malonyl-, 3-hydroxyisovaleryl-, hexenoyl-, decanoyl-, dodecanoyl-, dodecenoyl-, myristoyl-, tetradecenoyl-, hexadecenoyl-, stearoyl-, oleyl- and linoleyl-L-carnitine, showed a similar decreasing trend, passing from healthy subjects to patients at risk of or with Alzheimerās disease. These results suggest that serum acetyl-L-carnitine and other acyl-L-carnitine levels decrease along the continuum from healthy subjects to subjective memory complaint and mild cognitive impairment subjects, up to patients with Alzheimerās disease, and that the metabolism of some acyl-carnitines is finely connected among them. These findings also suggest that the serum levels of acetyl-L-carnitine and other acyl-L-carnitines could help to identify the patients before the phenotype conversion to Alzheimerās disease and the patients who would benefit from the treatment with acetyl-L-carnitine. However, further validation on a larger number of samples in a longitudinal study is needed before application to clinical practice.</p></div
Serum levels (Ī¼mol/L) of free L-carnitine and acyl-carnitines in the four studied groups.
<p>Serum levels (Ī¼mol/L) of free L-carnitine and acyl-carnitines in the four studied groups.</p
Serum levels of acyl-carnitines classified as VIP by PLS-DA.
<p>Box-plots show median (horizontal line in the box), 25th and 75th percentiles (edges of box), maximum and minimum values (whiskers) and outliers (Ā°,*) of acyl-carnitines concentrations (Ī¼mol/L) in the 4 groups of subjects. AD, Alzheimerās disease; MCI, mild cognitive impairment; SMC subjective memory complaint; HS, healthy subjects; (ā ) Significantly different from HS groups (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0155694#pone.0155694.t002" target="_blank">Table 2</a> for details).</p
Important features identified by PLS-DA.
<p>Twelve metabolites and 3 molar ratios show a VIP score > 1.3.The colored boxes indicate the relative concentrations of the corresponding metabolite or the relative value of ratios in each group.</p
Score plots for the PLS-DA model discriminating the 4 groups of subjects.
<p>Plots of the first two (A) and first three (B) components that explain, respectively, the 52% and the 56.3% of model variance. AD (red) samples were well separated from HS (light blue), while MCI (blue) and SMC (green) clustered in an intermediate zone.</p
ROC curves of selected acyl-carnitines.
<p>The plots show the optimal value of cutoff (ā¢), the value of full AUC with the 95% confidence intervals and the best delimitation of AUC (black solid line) for each metabolite.</p
Demographic and clinical characteristics of study groups.
<p>Demographic and clinical characteristics of study groups.</p